Bristol-Myers Squibb Company Research ReportOn June 12, 2013, Bristol-Myers Squibb Company (Bristol Myers Squibb) and AstraZeneca announced that they will continue to work with health authorities and scientific experts around the world to closely monitor the use of our GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance programs to ensure patients and physicians have a clear understanding of the risk/benefit profile of these medications. This announcement came after the American Diabetes Association (ADA) called for incretin-based therapies manufacturers to make available the patient-level data from clinical trials for an independent analysis of pancreatic safety. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/88a2_BMY]
Litigation Settlements, Data Compliance Reviews, And Clinical Trials Pave Way For Solid Footing In Healthcare - Research Report On Pfizer, Merck, Bristol-Myers Squibb, Keryx And Pacira Pharmaceuticals
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.